January 13, 2015 (Shareholders Foundation) - An investigation for current long-term investors in NASDAQ:MDXG shares was announced concerning possible breaches of fiduciary duties by certain MiMedx Group officers and directors.

The investigation by a law firm concerns whether certain MiMedx Group officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On September 4, 2013, MiMedx Group Inc confirmed that it is in receipt of an 'Untitled Letter' from the Food and Drug Administration ('FDA') in connection with MiMNedx Group Incs Amnion / Chorion Injectable products' eligibility for marketing solely under Section 361 of the Public Health Service Act.

On Dec. 31, 2014 MiMedx Group Inc (NASDAQ:MDXG) announced that it has received a subpoena from the Office of Inspector General ('OIG') of the Department of Health and Human Services ('HHS') in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.

MiMedx Group Inc said it intends to cooperate fully with the government in its investigation, and the Company will attempt to expedite the process.
MiMedx has already begun the process of producing the responsive documents. To the Company's knowledge, no proceedings have been initiated at this time. The Company cannot predict whether any proceeding might be initiated.

Shares of MiMedx Group Inc (NASDAQ:MDXG) declined from $11.73 per share on December 31, 2014, to as low as $8.922 per share on January 6, 2015.